Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease



Status:Recruiting
Conditions:Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:February 13, 2019
End Date:June 30, 2022
Contact:Pahoua Lee
Email:plee@rtix.com
Phone:952-698-9930

Use our guide to learn which trials are right for you!

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease (FORTE)

This is a prospective, multi-center, non-randomized post-market evaluation designed to
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.

This is a prospective, multi-center, non-randomized post-market evaluation designed to
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.

There will be 3 arms in the study, one for each configuration of the Fortilink IBF system
(Fortilink-C, Fortilink-TS and Fortilink-L). Up to 50 subjects will be enrolled in each study
arm for a total of up to 150 subjects at up to 20 sites in the United States (US) and
European Union (EU).

Inclusion Criteria:

- The subject is skeletally mature and at least 18 years of age.

- The subject has degenerative disc disease (DDD) of the cervical spine with
accompanying radicular symptom at one or two contiguous levels (Fortilink-C), or the
subject has DDD and ≤ Grade 1 spondylolisthesis of the lumbar spine at one or two
contiguous levels (Fortilink-TS and Fortilink-L).

- Subject plans to undergo one of the following procedures:

An anterior cervical interbody fusion at one to two continuous levels from C2-C3 to C7-T1
using autogenous or allogenic bone graft and supplemental fixation cleared and indicated
for use at the proposed treatment level(s) (Fortilink-C), or

An interbody fusion in the lumbar spine at one to two continuous levels from L1-L2 to L5-S1
using autogenous or allogenic bone graft and supplemental fixation cleared and indicated
for use at the proposed treatment level(s) (Fortilink-TS and Fortilink-L).

- The subject has undergone non-operative treatment of at least six weeks (Fortilink-C)
or at least six months (Fortilink-TS and Fortilink-L) prior to treatment with the IBF
system.

- The subject is willing and able to provide informed consent.

- The subject is willing and able to attend the protocol required follow-up visits and
examinations.

Exclusion Criteria:

- The subject has an active infection

- The subject has had prior fusion attempt(s) or is undergoing revision of a previously
implanted system at the involved level(s).

- The subject is a worker's compensation case, in active litigation related to the
procedure or is a prisoner or ward of the state.

- The subject meets one or more of the contraindications outlined in the IFU.

- The subject is pregnant, nursing, or is planning to become pregnant in the next year.

- The subject has documented evidence of current substance abuse.

- The subject has other concurrent medical condition that, in the opinion of the
investigator, does not make the subject a good candidate for the study.
We found this trial at
4
sites
Delray Beach, Florida 33484
2310
mi
from 91732
Delray Beach, FL
Click here to add this to my saved trials
10215 Fernwood Road
Bethesda, Maryland 20817
2275
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Boca Raton, Florida 33496
2312
mi
from 91732
Boca Raton, FL
Click here to add this to my saved trials
1659
mi
from 91732
Paducah, KY
Click here to add this to my saved trials